Natural Beauty Bio-Technology AI Stock Analysis
Want to see HK:0157 full AI Analyst Report?
Natural Beauty Bio-Technology (0157) AI Stock Analysis
Natural Beauty Bio-Technology
(HKEX:0157)
The score is primarily constrained by persistent cash burn and weak cash conversion, despite revenue recovery, renewed profitability, and a solid equity base. Technical momentum is mixed, while the negative P/E and absence of dividend support further limit the outlook.
Natural Beauty Bio-Technology (0157) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 100.11M
- Dividend Yield
- ―
- Average Volume (3M)
- 115.19K
- Price to Earnings (P/E)
- -15.0
- Beta (1Y)
- -0.10
- Revenue Growth
- 13.43%
- EPS Growth
- 7.72%
- Country
- Hong Kong
- Employees
- 597
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
Natural Beauty Bio-Technology Business Overview & Revenue Model
Company Description
Natural Beauty Bio-Technology Limited operates as an investment holding company, supplying skincare products and a comprehensive range of services across the People's Republic of China, Taiwan, and other global regions. Under its "Natural Beauty" bra...
Natural Beauty Bio-Technology Financial Statement Overview
Summary
Revenue grew 17% and profitability returned in 2025, while the equity base remained solid and leverage manageable. However, profitability is still low and persistent negative operating and free cash flow materially weaken financial quality.
Income Statement
65PositiveBalance Sheet
75PositiveCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 523.38M | 538.83M | 353.65M | 336.01M | 335.88M | 487.81M |
| Gross Profit | 227.26M | 293.34M | 202.33M | 200.34M | 165.33M | 281.80M |
| EBITDA | 4.98M | 66.15M | -65.50M | 22.91M | 15.09M | 85.23M |
| Net Income | -57.48M | 10.58M | -103.61M | -15.11M | -30.47M | 35.26M |
Balance Sheet | ||||||
| Total Assets | 1.01B | 931.55M | 772.93M | 882.58M | 883.53M | 937.16M |
| Cash, Cash Equivalents and Short-Term Investments | 116.16M | 112.12M | 116.51M | 166.81M | 168.61M | 197.08M |
| Total Debt | 424.66M | 319.30M | 212.13M | 186.29M | 143.48M | 129.07M |
| Total Liabilities | 587.05M | 457.56M | 325.34M | 308.06M | 286.07M | 279.24M |
| Stockholders Equity | 423.52M | 473.98M | 447.59M | 574.52M | 597.46M | 657.92M |
Cash Flow | ||||||
| Free Cash Flow | -136.88M | -93.91M | -54.96M | -47.39M | -35.98M | 4.67M |
| Operating Cash Flow | -58.33M | -25.66M | -13.75M | 21.72M | 8.33M | 42.78M |
| Investing Cash Flow | -74.73M | -68.95M | -40.17M | -67.61M | -38.77M | -31.21M |
| Financing Cash Flow | 169.03M | 84.61M | 15.34M | 42.63M | 13.21M | 10.42M |
Natural Beauty Bio-Technology Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0157, the sentiment is Negative. The current price of 0.43 is below the 20-day moving average (MA) of 0.45, below the 50-day MA of 0.44, and below the 200-day MA of 0.47, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 45.25 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0157.
Natural Beauty Bio-Technology Peers Comparison
Overall Rating
HK:104475Outperform
HK:214571Outperform
HK:382870.4Outperform
HK:015752Neutral
HK:699333Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 75Outperform | HKD 25.38B | 8.79 | 10.98% | 7.33% | 2.19% | 10.78% | |
| 71Outperform | HKD 9.05B | 11.21 | 25.77% | 6.18% | 23.19% | -22.44% | |
| 70Outperform | HKD 466.46M | 5.48 | 6.06% | 10.16% | 2.24% | -39.98% | |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 52Neutral | HKD 860.90M | -14.98 | -12.81% | ― | 13.43% | 7.72% | |
| 33Underperform | HKD 15.85B | -173.78 | -1.21% | 6.32% | -2.44% | 81.73% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0157 | Natural Beauty Bio-Technology | 0.43 | -0.08 | -15.69% | |
| HK:1044 | Hengan International Group Co | 21.86 | -3.80 | -14.82% | |
| HK:3828 | Ming Fai International Holdings | 0.64 | -0.23 | -26.61% | |
| HK:2145 | Shanghai Chicmax Cosmetics Co., Ltd. Class H | 22.72 | -58.13 | -71.90% | |
| HK:6993 | Blue Moon Group Holdings Ltd. | 2.85 | 0.24 | 9.03% | |
| HK:6883 | Eternal Beauty Holdings Limited | 2.03 | 0.05 | 2.53% |
Natural Beauty Bio-Technology Corporate Events
Natural Beauty Bio-Technology Wins Unanimous Backing for Multi-Year Eastern and ET Media Deals
Natural Beauty Bio-Technology Limited announced that shareholders have unanimously approved seven cooperation and supply agreements with various Eastern group and ET New Media partners at an extraordinary general meeting in Taipei. The resolutions, a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026
